In this issue of JAMA, 2 articles from the Netherlands report findings from meta-analyses that assess the prevalence of amyloid pathology as determined by biomarkers in persons with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI)1 and estimate the prevalence of amyloid positivity on amyloid-β positron emission tomography (PET) in a wide variety of dementia syndromes.2 These reports are the largest and most detailed to date and are critical assessments that help define the role of amyloid in the causation of cognitive impairment and dementia.
Rosenberg RN. Defining Amyloid Pathology in Persons With and Without Dementia SyndromesMaking the Right Diagnosis. JAMA. 2015;313(19):1913-1914. doi:10.1001/jama.2015.5361